Welcome to our dedicated page for Petros Pharmaceuticals news (Ticker: PTPI), a resource for investors and traders seeking the latest updates and insights on Petros Pharmaceuticals stock.
Petros Pharmaceuticals, Inc. reports developments in over-the-counter drug development programs and technology designed to support prescription-to-OTC switches. The company is developing a proprietary SaaS platform and Software as a Medical Device web application intended to assist pharmaceutical sponsors with FDA standards under the Additional Conditions for Nonprescription Use framework.
Recurring company updates include AI, big data, electronic health record, identity verification, cybersecurity and patient self-selection components of the platform; collaborations with software and data providers; application comprehension study results; and corporate actions affecting its balance sheet, subsidiary structure and trading status on OTC markets.
Petros Pharmaceuticals (Nasdaq: PTPI) announced the formation of a steering committee aimed at expanding access to its erectile dysfunction medication, Stendra® (avanafil), potentially moving towards Over the Counter (OTC) status. This initiative builds upon two years of efforts to enhance patient engagement. Key committee members include industry veterans experienced in Rx to OTC transitions. Stendra® generated approximately $30 million in gross revenues in 2019 and is covered for 75% of commercially insured lives. The company aims to accelerate Stendra®'s relaunch with a focused strategy.
Petros Pharmaceuticals (Nasdaq: PTPI) announces that its president and chief commercial officer, Fady Boctor, will present at NobleCon17 on January 20, 2021, at 9:00 AM ET. The presentation will be part of a virtual investor conference, free to attend for interested investors.
A video webcast will be available the following day on the company's website and on Channelchek, which will also rebroadcast the presentation next month. Petros focuses on innovative therapeutics addressing men's health issues, including erectile dysfunction and Peyronie's disease.
Synaptogenix, Inc. (OTC: SNPX) successfully spun off from Neurotrope Bioscience, focusing on neuro-restorative therapies for Alzheimer's and other neurodegenerative diseases. The lead compound, Bryostatin-1, has shown safety and cognitive improvement in clinical studies. Synaptogenix is advancing its NIH Phase 2 trial, extending dosing to six months, and exploring additional NIH grants. Management emphasizes strategic realignment to enhance shareholder value. The company is poised for growth amid rising interest in new treatment strategies for cognitive diseases.